Bioprex Medical develops permanent, non-leaching antimicrobial coatings for biomedical devices utilizing immobilized biocidal quaternary ammonium compounds. These coatings effectively kill bacteria on contact, preventing biofilm formation on various device surfaces. The technology offers a durable solution to reduce microbial contamination risks in medical applications.
Funding
Funding not disclosed
Founders
Product
Problem
Medical devices are susceptible to bacterial colonization and biofilm formation, leading to device-associated infections. Traditional antimicrobial coatings often leach biocides, risking contamination of bodily fluids and promoting antibiotic resistance.
Solution
Bioprex Medical develops permanent antimicrobial coatings for biomedical devices using immobilized biocidal quaternary ammonium compounds (QACs). Their patented technology ensures the coating kills bacteria on contact, preventing biofilm formation without leaching biocides into the body. The coating is adaptable to various surfaces and effective against a range of Gram-positive and Gram-negative bacteria. By preventing bacterial growth, Bioprex Medical's coatings significantly reduce the risk of medical device-associated infections.
Target Audience
The primary target audience includes medical device manufacturers seeking to enhance the antimicrobial properties of their products and healthcare providers aiming to reduce device-related infections.
Features
- Covalently bonded coating ensures permanent immobilization on the device surface.
- Hyperbranched polymers provide coating strength and hydrophobicity.
- Quaternary ammonium moieties (QACs) enable contact-killing of bacteria via electrostatic forces.
- Demonstrated effectiveness against both Gram-positive (e.g., S. Epidermis, S. Areus) and Gram-negative bacteria (e.g., E. Coli, P. Mirabilis).
- Non-leaching properties prevent contamination of bodily fluids.
- Coating maintains effectiveness even in the presence of peptides (e.g., from saliva).